Proactive Investors - Run By Investors For Investors

Adamas Finance Asia to invest up to US$5mln in a developer of needle-free injection technology

PharmaJet Inc’s innovation has received US Food & Drug Administration marketing clearance
sy
An end to painful injections?

Adamas Finance Asia Limited (LON:ADAM) said it plans to invest up to US$5mln into the developer of needle-free injection technology.

PharmaJet Inc’s innovative technology has received US Food & Drug Administration marketing clearance, is CE-Marked in Europe and is PQS certified by the World Health Organisation.

WATCH: Adamas Finance Asia to invest in developer of needle-free injection technology

PharmaJet, which has a distribution agreement with a company called Mundipharma, is hoping to raise between US$12-US$20mln to expand the business, particularly in Asia. 

The latest funding round could also pave the way to the stock market listing of PharmaJet on the Singapore exchange “and/or” NASDAQ in the US.

Asia-focused investment vehicle ADAM is ploughing its money into the business via a convertible bond structure. The convertible bond has a four-year maturity and an annual coupon of 10%.

READ: Adamas Finance Asia sees net asset value rise as investment opportunities beckon

The bond itself can be converted at ADAM’s discretion at a 40% discount to the pre-money valuation of the shares established by a liquidity event such as an IPO of PharmaJet.

“This investment represents another example of the attractive opportunities available to ADAM in capturing fundamental growth driven by Asia via a structured instrument which will provide income and potential capital gain," said chairman John Croft.

In the same announcement, ADAM said it still awaiting US$12.6mln of subscription funds from Fortune Insight following the sale Global Pharm Holdings Group.

View full ADAM profile View Profile

Adamas Finance Asia Timeline

Related Articles

1536105601_cobalt.jpg
September 05 2018
During the completion of its phase 1 exploration program at Bujagali and associated infill sampling, M2 Cobalt discovered six additional large-scale anomalies with highly anomalous rock and soil samples
computing symbols in cyberspace
January 15 2019
Its team of computer scientists designs algorithms that will be used by high-frequency traders, scientists doing genetic research and pharmaceutical companies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use